Trial ID or NCT#

NCT02717611

Status

not recruiting iconNOT RECRUITING

Purpose

A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Official Title

A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

David Iberri
David Iberri
Hematologist, Medical oncologist
Clinical Assistant Professor, Medicine - Hematology
Steven Coutre
Rondeep Brar
Rondeep Brar
Hematologist, Leukemia specialist, Medical oncologist
Clinical Associate Professor, Medicine - Hematology

Contact us to find out if this trial is right for you.

CONTACT

Cancer Clinical Trials Office
(650) 498-7061